| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 12/02/2025 | 07:30 | GlobeNewswire Inc. | Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board | EU:ALCJ | Crossject |
| 19/12/2024 | 07:30 | GlobeNewswire Inc. | Crossject confirms ZEPIZURE® supply chain readiness with another successful ISO audit for Quality Management System | EU:ALCJ | Crossject |
| 09/12/2024 | 07:30 | GlobeNewswire Inc. | Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement | EU:ALCJ | Crossject |
| 22/10/2024 | 07:30 | GlobeNewswire Inc. | Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization | EU:ALCJ | Crossject |
| 23/09/2024 | 18:00 | GlobeNewswire Inc. | Crossject reports financial results and business highlights for the first six months of 2024 | EU:ALCJ | Crossject |
| 22/08/2024 | 07:30 | GlobeNewswire Inc. | Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024 | EU:ALCJ | Crossject |
| 19/08/2024 | 17:30 | GlobeNewswire Inc. | Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment | EU:ALCJ | Crossject |
| 18/07/2024 | 07:30 | GlobeNewswire Inc. | Crossject achieves key ZEPIZURE® manufacturing milestone | EU:ALCJ | Crossject |
| 15/07/2024 | 07:30 | GlobeNewswire Inc. | Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference | EU:ALCJ | Crossject |
| 10/07/2024 | 07:30 | GlobeNewswire Inc. | Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine | EU:ALCJ | Crossject |
| 05/07/2024 | 10:09 | GlobeNewswire Inc. | Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social | EU:ALCJ | Crossject |
| 26/06/2024 | 07:30 | GlobeNewswire Inc. | Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study | EU:ALCJ | Crossject |
| 26/06/2024 | 07:30 | GlobeNewswire Inc. | Crossject met en perspective le potentiel de ZEPIZURE® à la lumière de l'étude de référence RAMPART et de sa propre étude de bioéquivalence récemment publiée. | EU:ALCJ | Crossject |
| 12/06/2024 | 07:30 | GlobeNewswire Inc. | Crossject appoints Dan Chiche, MD as Chief Medical Officer North America | EU:ALCJ | Crossject |
| 12/06/2024 | 07:30 | GlobeNewswire Inc. | Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du Nord | EU:ALCJ | Crossject |
| 04/06/2024 | 19:30 | GlobeNewswire Inc. | Crossject announces highly successful closing of its €8 million rights offering | EU:ALCJ | Crossject |
| 04/06/2024 | 19:30 | GlobeNewswire Inc. | Crossject annonce le vif succès de son augmentation de capital de 8 millions d’euros | EU:ALCJ | Crossject |
| 30/05/2024 | 10:30 | GlobeNewswire Inc. | Crossject annonce la publication de données cliniques sur ZEPIZURE® dans Neurology and Therapy | EU:ALCJ | Crossject |
| 30/05/2024 | 10:30 | GlobeNewswire Inc. | Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy | EU:ALCJ | Crossject |
| 02/05/2024 | 17:30 | GlobeNewswire Inc. | Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe | EU:ALCJ | Crossject |
| 02/05/2024 | 17:30 | GlobeNewswire Inc. | Crossject signe une extension géographique de l'accord de commercialisation de ZEPIZURE® en Europe | EU:ALCJ | Crossject |
| 30/04/2024 | 19:05 | GlobeNewswire Inc. | Crossject annonce le lancement d’une augmentation de capital | EU:ALCJ | Crossject |
| 25/04/2024 | 07:32 | GlobeNewswire Inc. | Crossject reports audited financial results for 2023 | EU:ALCJ | Crossject |
| 25/04/2024 | 07:32 | GlobeNewswire Inc. | Crossject communique ses résultats financiers audités pour 2023 | EU:ALCJ | Crossject |
| 02/04/2024 | 18:35 | GlobeNewswire Inc. | Crossject trading on Euronext to resume as usual on Wednesday April 3 | EU:ALCJ | Crossject |
| 02/04/2024 | 18:35 | GlobeNewswire Inc. | La cotation sur l’action de Crossject à Euronext reprendra comme d’habitude le mercredi 3 avril | EU:ALCJ | Crossject |
| 02/04/2024 | 10:30 | GlobeNewswire Inc. | Crossject advances in its U.S. Strategy and reports Financial Results for 2023 | EU:ALCJ | Crossject |
| 02/04/2024 | 10:30 | GlobeNewswire Inc. | Crossject poursuit sa stratégie de développement aux États-Unis et publie ses résultats financiers pour 2023 | EU:ALCJ | Crossject |
| 08/03/2024 | 07:30 | GlobeNewswire Inc. | Le Score de l’index Egalité femmes-hommes chez Crossject atteint 96/100 en 2024 | EU:ALCJ | Crossject |
| 08/03/2024 | 07:30 | GlobeNewswire Inc. | Crossject gender equality score reaches 96/100 in 2024 | EU:ALCJ | Crossject |
